Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Feb;8(1):e001499.
doi: 10.1136/openhrt-2020-001499.

Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis

Affiliations
Observational Study

Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis

Stuart Pocock et al. Open Heart. 2021 Feb.

Abstract

Objective: To assess associations of health-related quality of life (HRQoL) with patient profile, resource use, cardiovascular (CV) events and mortality in stable patients post-myocardial infarction (MI).

Methods: The global, prospective, observational TIGRIS Study enrolled 9126 patients 1-3 years post-MI. HRQoL was assessed at enrolment and 6-month intervals using the patient-reported EuroQol-5 dimension (EQ-5D) questionnaire, with scores anchored at 0 (worst possible) and 1 (perfect health). Resource use, CV events and mortality were recorded during 2-years' follow-up. Regression models estimated the associations of index score at enrolment with patient characteristics, resource use, CV events and mortality over 2-years' follow-up.

Results: Among 8978 patients who completed the EQ-5D questionnaire, 52% reported 'some' or 'severe' problems on one or more health dimensions. Factors associated with a lower index score were: female sex, older age, obesity, smoking, higher heart rate, less formal education, presence of comorbidity (eg, angina, stroke), emergency room visit in the previous 6 months and non-ST-elevation MI as the index event. Compared with an index score of 1 at enrolment, a lower index score was associated with higher risk of all-cause death, with an adjusted rate ratio of 3.09 (95% CI 2.20 to 4.31), and of a CV event, with a rate ratio of 2.31 (95% CI 1.76 to 3.03). Patients with lower index score at enrolment had almost two times as many hospitalisations over 2-years' follow-up.

Conclusions: Clinicians managing patients post-acute coronary syndrome should recognise that a poorer HRQoL is clearly linked to risk of hospitalisations, major CV events and death.

Trial registration number: ClinicalTrials.gov Registry (NCT01866904) (https://clinicaltrials.gov).

Keywords: coronary artery disease; myocardial infarction; quality of healthcare.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SP has received research grant support from AstraZeneca. DBB has received speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Merck and Sanofi. RO has received research grant support from AstraZeneca. JC has received research grant support from AstraZeneca and consulting honoraria from MicroPort, APT Medical and JW Medical. MGC has received speaker/consulting honoraria and/or research grant support from AstraZeneca, Medtronic, Abiomed and Merit Medical. SG has received speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, CSL Behring, Daiichi Sankyo/American Regent, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Servier and Tenax Pharmaceuticals. CBG has received consulting honoraria and/or research grant support from Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Metronic, Pfizer, Salix Pharmaceuticals, Sanofi, Takeda and The Medicines Company. JCN has received speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, Merck, Novartis, Pfizer and Sanofi. TS has received speaker/consulting honoraria and/or research grant support from Astellas, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer and Sanofi. DW has received speaker/consulting honoraria and/or research grant support from AstraZeneca, Bayer, Berlin-Chemie, Biotronik and Novartis. SY has received speaker/consulting honoraria and/or research grant support from Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim and BMS. KH, CM and KAS are employees of AstraZeneca.

Figures

Figure 1
Figure 1
(A) Distributions of the EQ-5D items and (B) the consequent EQ-5D index score and VAS score in 8978 patients at enrolment. EQ-5D, EuroQol-5 dimension; VAS, Visual Analogue Scale.
Figure 2
Figure 2
The associations of (A) baseline EQ-5D index score and (B) baseline VAS score with mortality and the composite outcome of CV death, MI, stroke and unstable angina requiring urgent revascularisation (using Poisson regression models with and without adjustment for other patient variables). Adjusted for variables in the TIGRIS index model: age ≥65 years; diabetes; second prior MI; chronic kidney disease; heart failure; peripheral artery disease; CV event in past 6 months; prior major bleed; medical management only of index MI; on diuretics at enrolment. CV, cardiovascular; EQ-5D, EuroQol-5 dimension; MI, myocardial infarction; VAS, Visual Analogue Scale.
Figure 3
Figure 3
Health resource use over 2-years’ follow-up by baseline self-rated health in 7846 patients with health resource data at every visit (using OLS regression models with and without adjustment for other patient variables). (A) EQ-5D index score and (B) EQ-5D VAS score adjusted for variables in the TIGRIS index model: age ≥65 years; diabetes; second prior MI; chronic kidney disease; heart failure; peripheral artery disease; CV event in past 6 months; prior major bleed; medical management only of index MI; on diuretics at enrolment. CV, cardiovascular; EQ-5D, EuroQol-5 dimension; ER, emergency room; GP, general practitioner; MI, myocardial infarction; OLS, Ordinary Least Squares; VAS, Visual Analogue Scale.

References

    1. Doll JA. Quality of life after myocardial infarction: more PROgress needed. Heart 2020;106:8–9. 10.1136/heartjnl-2019-315871 - DOI - PubMed
    1. EuroQol Group . EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. 10.1016/0168-8510(90)90421-9 - DOI - PubMed
    1. Dyer MTD, Goldsmith KA, Sharples LS, et al. . A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010;8:13. 10.1186/1477-7525-8-13 - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence (NICE) . Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420. London: NICE, 2016. Available: https://www.nice.org.uk/guidance/ta420 [Accessed 20 Jul 2020].
    1. Munyombwe T, Hall M, Dondo TB, et al. . Quality of life trajectories in survivors of acute myocardial infarction: a national longitudinal study. Heart 2020;106:33–9. 10.1136/heartjnl-2019-315510 - DOI - PubMed

Publication types

Associated data